Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database
Pancreatic cancer is the fourth leading cause of cancer mortality in the United States [1]. In patients with localized disease, surgical resection remains central to curative-intent treatment, but surgery alone is associated with high rates of recurrence [2,3]. Increasingly, a neoadjuvant approach to pancreatic cancer treatment is gaining interest [2,4]. Its advantages include treatment of better perfused/better oxygenated tumor, preoperative shrinkage of tumor with potential for increased margin-negative resection rate, increased chemotherapy delivery, and earlier treatment of micrometastatic disease [3].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Michael Xiang, Gregory M. Heestand, Daniel T. Chang, Erqi L. Pollom Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Radiology | USA Health